Graft vs host disease impacts overall survival post allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia/lymphoma.

Content Provider	Europe PMC
Author	Damlaj, Moussab Snnallah, Mohammad Alhejazi, Ayman Ghazi, Samer Alahmari, Bader Alaskar, Ahmed Al-Zahrani, Mohsen
Copyright Year	2018
Abstract	AIMTo examine the outcome and prognostic factors for high risk patients with acute lymphoblastic leukemia/lymphoma (ALL/LBL) who underwent allogeneic hematopoietic stem cell transplantation (HCT) at our center during the period of 2010-2017METHODSAfter due institutional review board approval, patients with high risk ALL/LBL post HCT were identified and included. All records were retrospectively collected. Time to event analysis was calculated from the date of HCT until event of interest or last follow up with Kaplan-Meir means. Cox regression model was used for multivariable analysis calculation.RESULTSA total of 69 patients were enrolled and examined with a median age of 21 (14-61). After a median follow up of 15 mo (2-87.3), the 2-year cumulative incidence of relapse, cumulative incidence of non-relapse mortality, progression free survival and overall survival (OS) were 34.1%, 10.9%, 54.9% and 62.8%, respectively. In a multivariable analysis for OS; acute graft vs host disease (GVHD) and chronic GVHD were significant with corresponding hazard ratio 4.9 (1.99-12; P = 0.0007) and 0.29 (0.1-0.67; P = 0.0044), respectively.CONCLUSIONAllogeneic-HCT for high risk ALL/LBL resulted in promising remissions particularly for patients with cGVHD.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6304336&blobtype=pdf
Journal	World Journal of Transplantation [World J Transplant]
Volume Number	8
DOI	10.5500/wjt.v8.i7.252
PubMed Central reference number	PMC6304336
Issue Number	7
PubMed reference number	30596032
e-ISSN	22203230
Language	English
Publisher	Baishideng Publishing Group Inc
Publisher Date	2018-11-01
Access Restriction	Open
Rights License	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Subject Keyword	Acute lymphoblastic leukemia Allogeneic hematopoietic stem cell transplant Lymphoblastic lymphoma Complete remission
Content Type	Text
Resource Type	Article
Subject	Transplantation